Research analysts at Cantor Fitzgerald upped their FY2022 earnings estimates for shares of Prothena in a research report issued on Wednesday, December 21st. Cantor Fitzgerald analyst C. Duncan now anticipates that the biotechnology company will post earnings of ($3.01) per share for the year, up from their prior estimate of ($3.04). Cantor Fitzgerald currently has a "Overweight" rating and a $98.00 target price on the stock. The consensus estimate for Prothena's current full-year earnings is ($2.86) per share. Cantor Fitzgerald also issued estimates for Prothena's FY2023 earnings at ($3.68) EPS.
https://www.marketbeat.com/instant-alerts/nasdaq-prta-analyst-earnings-estimates-2022-12-2-3/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.